Lymphotec Files IND In Japan For Brain Tumor Immunotherapy
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based medical venture firm Lymphotec has filed an NDA in Japan for activated autologous lymphocytes to treat patients with malignant brain tumors